Advisors Asset Management Inc. Grows Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Advisors Asset Management Inc. increased its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 17.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 7,195 shares of the company’s stock after purchasing an additional 1,046 shares during the quarter. Advisors Asset Management Inc.’s holdings in Medpace were worth $2,390,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Centaurus Financial Inc. lifted its stake in shares of Medpace by 2.0% in the 3rd quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock valued at $505,000 after purchasing an additional 29 shares during the period. Lindbrook Capital LLC lifted its stake in shares of Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after purchasing an additional 29 shares during the period. HBK Sorce Advisory LLC lifted its stake in shares of Medpace by 0.5% in the 4th quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company’s stock valued at $1,789,000 after purchasing an additional 29 shares during the period. Assetmark Inc. lifted its stake in shares of Medpace by 20.1% in the 4th quarter. Assetmark Inc. now owns 173 shares of the company’s stock valued at $57,000 after purchasing an additional 29 shares during the period. Finally, Proficio Capital Partners LLC lifted its stake in shares of Medpace by 4.1% in the 4th quarter. Proficio Capital Partners LLC now owns 730 shares of the company’s stock valued at $243,000 after purchasing an additional 29 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Robert W. Baird raised their target price on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $381.44.

Medpace Trading Up 1.4 %

Shares of NASDAQ:MEDP opened at $324.23 on Friday. The stock has a fifty day simple moving average of $337.72 and a two-hundred day simple moving average of $339.89. The stock has a market capitalization of $9.88 billion, a price-to-earnings ratio of 25.67, a PEG ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 12-month low of $302.01 and a 12-month high of $459.77.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.